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ABSTRACT 
It is speculated that measurement of serum theophylline concentration 
alone, without concomitant caffeine level determination, may lead to a 
false negative (normal) pneumocardiogram due to possible existence of 
therapeutic caffeine level resulting from the methylation of theophyl- 
line. Treatment of neonatal apnea with theophylline as documented by a 
normal follow-up pneumocardiogram should be considered successful only 
when the levels of both theophylline and caffeine have been documented 
subtherapeutic at time of re-test. 
INTRODUCTION 
Effective treatment of apnea of prematurity can be accomplished with the 
administration of theophylline (1) or caffeine (2). Assessment of the 
effectiveness of theophylline therapy in managing apnea of prematurity 
(3) can now be performed utilizing the pneumocardiogram (4, 5), a 12 
hour recording of respiration and heart rate on magnetic tape. Thera- 
peutic serum concentration of theophylline in the range of 7-15 ug/ml, 
and of caffeine as low as 3-4 pg/ml can abolish apnea and regularize 
neonatal breathing patterns (6). It has been documented that intercon- 
version of theophylline and caffeine occurs in the newborn infant (7), 
with a considerably higher ratio of caffeine to theophylline in neonates 
treated with theophylline (8) when compared to the ratio of theophylline 
to caffeine in neonates treated with caffeine (9). It is possible that 
the reported efficacy of low dose theophylline therapy (10) with lower 
theophylline plasma concentrations (2.8-4.8 ug/ml) is due to the poten- 
tiating effect of unmeasured caffeine concentration resulting from 
methylation of theophylline. Measurement of theophylline level alone 
is therefore insufficient in monitoring the clinical course of the 
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premature infant with apnea and determination of serum caffeine level 
should also be included as these two methylxanthines are both pharma- 
cologically active. 
CURRENT MANAGEMENT PROTOCOLS 
Infants with abnormal pneumocardiogram are started on theophylline with 
a loading dose of 6 mg/kg. Maintenance dose is 2 mg/kg given initially 
every 12 hours. The maintenance dose is adjusted according to the serum 
theophylline level (8-10 ug/ml) and sometimes given every 8 hours. The 
pneumocardiogram is repeated when the therapeutic range of serum theo- 
phylline concentration has been attained. The subsequent management of 
these infants depends on the result of this repeat pneumocardiogram and 
can be categorized as follows. 
Abnormal Pneumocardipgram Despite Medication 
Infants whose pneumocardiogram remains abnormal despite adequate serum 
theophylline level undergo further evaluation, including an electro- 
encephalogram, and are treated with phenobarbital when indicated. The 
parents of these infants are instructed in the use of a home apnea mon- 
itor and proper performance of cardiopulmonary resuscitation before the 
patient's discharge. These infants are followed in the neonatal clinic 
and monitored for anv evidence of theophylline toxicity. The medication 





normal serum drug level. The majority of infants are s 
discontinued from the theophylline therapy and the home 
in four to six months and are asymptomatic on phenobarb 






Normal Pneumocardiogram on Medication 
Infants whose apnea has responded to administration of theophylline, as 
evidenced by a normal pneumocardiogram on repeat test, are sent home on 
medication without a home apnea monitor. After 4-6 weeks, the theophyl- 
line therapy is discontinued for approximately 72 hours while the infant 
is on an apnea monitor. When the theophylline level is determined to be 
subtherapeutic or near zero, a repeat pneumogram is performed. If the 
pneumogram is abnormal, theophylline is resumed until a therapeutic 
level is attained and the infant has a normal repeat pneumocardiogram. 
The infant is maintained on medication for another l-2 months. The dur- 
ation of treatment with theophylline has been variable but these infants 
usually have normal pneumocardiograms when theophylline is discontinued 
at about 44 weeks conceptional age. 
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Normal Pneumocardiogram when Medication is Discontinued 
Infants whose repeat pneumocardiogram is normal after the theophylline 
has been discontinued for about 72 hours, with serum theophylline level 
near zero, are considered to be resolved of apnea. 
HYPOTHESIS 
The concern and subject of this presentation are the infants who have 
normal repeat pneumocardiograms after discontinuation of theophylline 
when the infant is shown to have a subtherapeutic serum theophylline 
level. It is speculated that measurement of serum theophylline concen- 
tration without concomitant caffeine level determination may lead to a 
false negative (normal) pneumocardiogram due to the possible existence 
of a therapeutic caffeine level resulting from the methylation of 
theophylline. It has been shown that premature newborns have a remark- 
ably slow elimination of theophylline (14-57 hours) and caffeine (40 - 
231 hours). Bory et al (9) have found theophylline to disappear from 
the plasma three days after cessation of therapy, whereas caffeine was 
still present nine days after therapy. Continued formation of caffeine 
after the cessation of theophylline thearpy could also result in a 
higher caffeine concentration. 
CONCLUSION 
Reliance on a subtherapeutic or near zero serum level of theophylline 
alone without a concomitant subtherapeutic level of caffeine may render 
the results of the follow-up pneumocardiogram unreliable. Treatment of 
neonatal apnea with theophylline as documented by a normal follow-up 
pneumocardiogram should be considered successful only when the levels of 
both theophylline and caffeine have been documented subtherapeutic at 
the time of re-test. We are presently utilizing a micro scale method 
using high performance liquid chromatography (HPLC) in the measurement 
of both theophylline and caffeine concentrations. Our recent capability 
to determine the levels of these two methylxanthines will allow us to 
test the hypothesis I have presented. 
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